Research Article

The Risk Correlation between N7-Methylguanosine Modification-Related IncRNAs and Survival Prognosis of Oral Squamous Cell Carcinoma Based on Comprehensive Bioinformatics Analysis

Yanglong Xu,1 Xue Zou,2 and Jie Mei3

1Department of General Dentistry, Stomatological Hospital Affiliated to Zunyi Medical University, China
2Department of Periodontics, Stomatological Hospital Affiliated to Zunyi Medical University, China
3Stomatological Hospital, Southern Medical University, China

Correspondence should be addressed to Jie Mei; meijie@smu.edu.cn

Received 5 June 2022; Revised 23 June 2022; Accepted 2 July 2022; Published 24 August 2022

Academic Editor: Yaodong Gu

Copyright © 2022 Yanglong Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. N7-methylguanosine modification-related IncRNAs (m7G-related IncRNAs) are involved in progression of many diseases. This study was aimed at revealing the risk correlation between N7-methylguanosine modification-related IncRNAs and survival prognosis of oral squamous cell carcinoma. Methods. In the present study, coexpression network analysis and univariate Cox analysis were used to obtained 31 m7G-related mRNAs and 399 m7G-related IncRNAs. And the prognostic risk score model of OSCC patients was evaluated and optimized through cross-validation. Results. Through the coexpression analysis and risk assessment analysis of m7G-related prognostic mRNAs and IncRNAs, it was found that six m7G-related prognostic IncRNAs (AC005332.6, AC010894.1, AC068831.5, AL035446.1, AL513550.1, and HHLA3) were high-risk IncRNAs. Three m7G-related prognostic IncRNAs (AC007114.1, HEIH, and LINC02541) were protective IncRNAs. Then, survival curves were drawn by comparing the survival differences between patients with high and low expression of each m7G-related prognostic IncRNA in the prognostic risk score model. Further, risk curves, scatter plots, and heat maps were drawn by comparing the survival differences between high-risk and low-risk OSCC patients in the prognostic model. Finally, forest maps and the ROC curve were generated to verify the predictive power of the prognostic risk score model. Our results will help to find early and accurate prognostic risk markers for OSCC, which could be used for early prediction and early clinical intervention of survival, prognosis, and disease risk of OSCC patients in the future.

1. Introduction

Oral squamous cell carcinoma (OSCC) is a malignant tumor occurring in oral cavity with squamous cell as the main cell. Cancer cells can occur in gingival, hard palate, tongue, buccal mucosa, lips, and other organs [1]. It is the most malignant and harmful tumor of the head and neck, accounting for about 50% of the incidence of the head and neck squamous cell carcinoma [2]. Due to the rich blood flow and complex anatomical structure of oral and maxillofacial region, OSCC surgery often cannot completely remove the tumor [3]. At the same time, OSCC is prone to lymph node metastasis and postoperative recurrence, so its prognosis is poor [4]. Therefore, it is particularly urgent to identify new prognostic genes to accurately predict the prognosis of OSCC patients at an early stage.

Long noncoding RNAs (lncRNAs) are noncoding RNAs with a length of more than 200 nucleotides. They are functional RNA molecules that cannot be translated into proteins, but they are involved in a variety of biological regulation processes in cells of the body, such as epigenetic regulation, cell cycle regulation, and cell differentiation regulation [5, 6]. N7-methylguanine (m7G) is a metabolite of RNA methylation, which can be produced by methylation agents and is used as probes for protein-RNA interactions and as a key component of RNA sequencing methods [7, 8]. Some studies have shown that N7-methylguanosine modification-related IncRNAs (m7G-related IncRNAs) are...
involving in maintaining RNA stability, processing, nucleation, translation, and other functions, affecting the occurrence and progression of many diseases [9–13]. However, as far as we know, no studies on m7G-related lncRNAs have been reported in OSCC. This study was aimed at revealing the risk correlation between N7-methylguanosine modification-related lncRNAs and survival prognosis of oral squamous cell carcinoma.

In this study, we constructed a prognostic risk score model for OSCC based on the new m7G-related lncRNAs; conducted risk assessment, survival analysis, and risk analysis for OSCC patients; and finally verified the accuracy and independent predictive ability of the prognostic risk model. The purpose of this study was to find early and accurate prognostic risk markers for OSCC, which could be used for early prediction and early clinical intervention of survival, prognosis, and disease risk of OSCC patients in the future.

2. Materials and Methods

2.1. Acquisition and Cleaning of Gene Matrix and Clinical Data. The transcriptome expression matrix of all OSCC samples and clinical data of patients were obtained from The Cancer Genome Atlas (TCGA) database (https://tcga-data.nci.nih.gov/tcga), which provides clinical information and genome variation, mRNA expression, miRNA expression, methylation, and other data on various human cancers, making it an important data source for cancer researchers [14, 15]. A total of 83 samples were collected, including 70 OSCC tissue samples and 13 normal tissue samples. In addition, we used custom Perl scripts to clean and organize all the data for further bioinformatics analysis and statistical analysis.

2.2. Identification of m7G-Related mRNAs and IncRNAs. Firstly, the transcriptome expression matrix of all OSCC samples was divided into mRNA and lncRNA expression profiles using customized Perl scripts and human gene profiles. Then from MSigDB database (http://www.gSEA-msigdb.org/gsea/login.jsp) [16] to arrange m7G-related mRNAs list, then extracted each relative expression of m7G-related mRNAs via R package limma [17] from OSCC gene matrix. Finally, the lncRNA expression matrix and the list of m7G-related mRNAs were selected respectively; the expression values of repeated genes and normal samples were removed; the coexpression of lncRNAs with m7G-related mRNAs was identified through the cyclic calculation of correlation test, named as m7G-related IncRNAs; and the expression matrix was obtained [18]. The cutoff criterion was Pearson correlation coefficient > 0.4 and P value < 0.001.

2.3. Identification of m7G-Related Prognostic IncRNAs. First, the survival data of all patients (including survival time and survival status) were collated, and the m7G-related lncRNA expression matrix was combined with the survival data of patients (only patients with complete information were included). Then, Kaplan-Meier (KM) analysis and univariate Cox analysis methods [19, 20] were used to test the correlation between m7G-related lncRNA expression levels and survival time and status of patients via R package survival [21], so as to identify the m7G-related prognostic IncRNAs. Only P values less than 0.05 for the two analysis methods were considered statistically significant.

2.4. Construction of Prognostic Risk Score Model for OSCC. We used the m7G-related prognostic lncRNA expression matrix with survival information as input file to construct Cox model through R package survival and optimized the model by calculating AIC value, so as to obtain the formula of prognostic risk score model [22, 23]. We then calculated each OSCC patient’s risk scores based on this formula and compared the risk scores with the median risk score to predict whether each patient was a high- or low-risk patient.

2.5. Analysis of Prognostic Gene Coexpression Network. First, we extracted the list of m7G-related prognostic lncRNAs involved in prognostic model construction and the table of coexpression relationship between m7G-related prognostic mRNAs and IncRNAs. Then, by customizing Perl scripts, we sorted out and obtained coexpression relations and node attributes of m7G-related prognostic mRNAs and IncRNAs, which were used as input files to build coexpression networks [24]. Finally, we visualized the prognostic gene coexpression network using Cytoscape software [25]. In the gene coexpression network, hub genes represent a small proportion of nodes with maximal information exchange with other nodes. Cytoscape is an open source software for visualizing complex networks and integrating these with any type of attribute data.

2.6. Risk Assessment of m7G-Related Prognostic IncRNAs. In order to identify which m7G-related prognostic IncRNAs in the prognostic model are high-risk IncRNAs (hazard ratio, HR > 1) and which are protective IncRNAs (HR < 1), we analyzed the association between m7G-related prognostic IncRNAs and mRNAs [26] and conducted a risk assessment for these IncRNAs via packages ggalluvial, ggplot2, and dplyr [27, 28]. The result was represented by a Sankey diagram [29].

2.7. Survival Analyses of m7G-Related Prognostic IncRNAs. Through R package survival, survival analyses were performed on all m7G-related prognostic IncRNAs involved in the establishment of the prognostic risk score model to explore the relationship between m7G-related prognostic IncRNA expression and survival prognosis of OSCC patients [30]. Prognostic models or risk scores are frequently used to aid individualize risk assessment for diseases with multiple, complex risk factors and diagnostic challenges. According to the median m7G-related prognostic IncRNA expression value, all OSCC patients were divided into high m7G-related prognostic IncRNA expression group and low m7G-related prognostic IncRNA expression group, and then, survival analysis function was defined to compare whether there was statistical difference in survival rate between the two groups [31]. Results were visualized by survival curves [32].
2.8. Risk Analysis of the Prognostic Risk Score Model for OSCC. To further elucidate the relationship between patient survival time, survival status, m7G-related prognostic lncRNA expression levels, and risk scores, we conducted a comprehensive risk analysis for OSCC patients with high- and low-risk groups. Results were displayed by a risk curve, a survival scatter plot, and a risk gene heat map [33, 34].

2.9. Independent Prognostic Analysis of the Prognostic Risk Score Model for OSCC. We performed independent prognostic analyses of the prognostic risk score model to verify whether risk score could be an independent prognostic factor for OSCC patients [35]. Univariate and multivariate independent prognostic analyses were performed using the R package survival by extracting and combining risk information (including survival time, survival status, risk score, and m7G-related prognostic lncRNA expression matrix) and clinical trait lists (including patients’ age, gender, cancer grade, and stage) of all patients. The results were shown in forest maps [36].

2.10. ROC Curve Analyses of Several Clinical Traits in the Prognostic Model. Receiver operating characteristic (ROC) curve, also known as sensitivity curve, is a comprehensive index reflecting the continuous variables of sensitivity and specificity [37]. Generally, the relationship between the two is revealed by using the composition method. The larger the area under ROC curve (AUC), the higher the diagnostic accuracy of the test [38]. To test the predictive performance of OSCC prognostic risk score model, R package survival ROC was used to perform KM analysis on patients’ survival time, survival status, risk score, and clinical characteristics (age, gender, tumor stage, and grade), and ROC curves of risk score and clinical traits were plotted [39, 40].

| IncRNAs       | HR    | HR.95L | HR.95H | KM_P value | Cox_P value |
|---------------|-------|--------|--------|------------|-------------|
| TMEM99        | 1.177 | 1.094  | 1.265  | 0.00111836 | 1.13E-05    |
| HHLA3         | 1.167 | 1.075  | 1.267  | 0.007342318| 0.000213266 |
| AC010894.1    | 2.447 | 1.687  | 3.550  | 0.007956686| 2.38E-06    |
| ALS13550.1    | 2.097 | 1.463  | 3.006  | 0.002772334| 5.52E-05    |
| LINCO2541     | 0.576 | 0.524  | 0.632  | 0.009523161| 0.002882225 |
| AL035446.1    | 1.270 | 1.072  | 1.504  | 0.001398622| 0.005652859 |
| MAPKAPK5-AS1  | 1.517 | 1.224  | 1.881  | 0.006793084| 0.00141708  |
| CASC9         | 1.158 | 1.074  | 1.249  | 0.001601384| 0.00136753  |
| FLJ20021      | 1.062 | 1.019  | 1.107  | 7.95E-05   | 0.00372095  |
| AC007114.1    | 0.560 | 0.386  | 0.814  | 0.00430497 | 0.00633620  |
| AC010326.3    | 1.374 | 1.101  | 1.715  | 0.005999112| 0.004811556 |
| PCCA-DT       | 1.191 | 1.071  | 1.326  | 0.002625784| 0.001239526 |
| AP001505.1    | 1.124 | 0.816  | 1.219  | 0.003673122| 0.004236502 |
| AC068831.5    | 2.156 | 1.401  | 3.320  | 0.00403799 | 0.00478102  |
| AC005332.6    | 1.342 | 1.076  | 1.672  | 0.00878354 | 0.008830636 |
| HEIH          | 0.414 | 0.247  | 0.696  | 0.00520546 | 0.005809747 |

Table 1: Identification of m7G-related prognostic lncRNAs.

| IncRNAs (Expβ) | Coef (β) | HR value |
|----------------|----------|----------|
| HHLA3          | 0.177    | 1.193    |
| AC010894.1     | 1.227    | 3.410    |
| ALS13550.1     | 1.011    | 2.748    |
| LINCO2541      | -0.319   | 0.726    |
| AL035446.1     | 0.301    | 1.352    |
| AC007114.1     | -0.737   | 0.478    |
| AC068831.5     | 0.793    | 2.210    |
| AC005332.6     | 0.539    | 1.715    |
| HEIH           | -0.800   | 0.449    |

Calculation formula: Risk score = Expβ1 × β1 + Expβ2 × β2 + Expβ3 × β3 + Expβi × βi.

Table 2: Coefficient profiles of the nine m7G-related prognostic lncRNAs.

| IncRNAs (Expβ) | Coef (β) | HR value |
|----------------|----------|----------|
| HHLA3          | 0.177    | 1.193    |
| AC010894.1     | 1.227    | 3.410    |
| ALS13550.1     | 1.011    | 2.748    |
| LINCO2541      | -0.319   | 0.726    |
| AL035446.1     | 0.301    | 1.352    |
| AC007114.1     | -0.737   | 0.478    |
| AC068831.5     | 0.793    | 2.210    |
| AC005332.6     | 0.539    | 1.715    |
| HEIH           | -0.800   | 0.449    |

Calculation formula: Risk score = Expβ1 × β1 + Expβ2 × β2 + Expβ3 × β3 + Expβi × βi.

Table 3: Coefficient profiles of the nine m7G-related prognostic lncRNAs.
3. Results

3.1. Identification of m7G-Related IncRNAs. We downloaded 60,660 gene transcription expression matrices from TCGA database, including 16,798 IncRNAs and 19,926 mRNAs. According to MSigDB database and OSCC mRNA matrix, 31 m7G-related mRNAs were obtained. Then, 399 m7G-related IncRNAs were identified through coexpression network analysis. For the expression matrix and coexpression relationship of m7G-related IncRNAs, see Supplementary Files (m7G-lncRNAs_exp.xls and co-exp_rel.xls).

3.2. Identification of m7G-Related Prognostic IncRNAs. Combined with KM analysis and univariate Cox analysis, we identified 16 m7G-related prognostic IncRNAs (as shown in Table 1). Three IncRNAs, LINC02541, AC007114.1, and HEIH, were low-risk IncRNAs (HR values < 1), and the rest were high-risk IncRNAs (HR values > 1). The P values of IncRNAs identified by the two methods were all less than 0.05.

3.3. The Prognostic Risk Score Model for OSCC. We performed univariate Cox analysis on 16 m7G-related prognostic IncRNAs and optimized 9 m7G-related prognostic IncRNAs, among which LINC02541, AC007114.1, and HEIH were low-risk IncRNAs (HR value < 1) and HHLA3, AC010894.1, AL513550.1, AL035446.1, AC068831.5, and AC005332.6 were high-risk IncRNAs (HR value > 1). The prognostic risk score model of OSCC patients was evaluated and optimized through cross-validation. IncRNAs and prognostic model formula that comprised the prognostic risk score model are shown in Tables 2 and 3. The raw data related to the prognostic model are detailed in Supplementary Files (risk.xls and uniSigExp.xls).

3.4. The Coexpression Network of m7G-Related Prognostic IncRNAs and mRNAs. A total of 10 m7G-related prognostic mRNAs and 9 m7G-related prognostic IncRNAs were identified through coexpression network analysis. For details about the coexpression relationship between the m7G-related prognostic IncRNAs and mRNAs, see Supplementary Files (coexp_network.xls). Coexpression network was used to visualize the correlation between the 10 m7G-related prognostic mRNAs and 9 m7G-related prognostic IncRNAs (Figure 1).

3.5. Risk Identification of m7G-Related Prognostic IncRNAs. Through the coexpression analysis and risk assessment analysis of m7G-related prognostic mRNAs and IncRNAs, it was found that six m7G-related prognostic IncRNAs (AC005332.6, AC010894.1, AC068831.5, AL035446.1, AL513550.1, and HHLA3) were high-risk IncRNAs. Three
m7G-related prognostic lncRNAs (AC007114.1, HEIH, and LINC02541) were protective lncRNAs. The Sankey diagram showed the risk profile of all m7G-related prognostic lncRNAs (Figure 2).

### 3.6. Survival Curves of m7G-Related Prognostic lncRNAs
Survival curves were drawn by comparing the survival differences between patients with high and low expression of each m7G-related prognostic lncRNA in the prognostic risk score model. As shown in Figure 3, the survival of six m7G-related prognostic lncRNAs (AC005332.6, AC010894.1, AC068831.5, AL035446.1, AL513550.1, and HHLA3) with the high expression group was significantly lower than that with the low expression group ($P < 0.05$), while the survival of the other three m7G-related prognostic lncRNAs (AC007114.1, HEIH, and LINC02541) with the high expression group was significantly higher than that with the low expression group ($P < 0.05$).

### 3.7. Risk Assessment of the Prognostic Risk Score Model for OSCC
Risk curves, scatter plots, and heat maps were drawn by comparing the survival differences between high-risk and low-risk OSCC patients in the prognostic risk score model. As shown in Figure 4(a), the risk score of OSCC patients in the high-risk group was significantly higher than that in the low-risk group ($P < 0.05$). As shown in Figure 4(b), there were significantly more deaths in the high-risk group than in the low-risk group. In addition, Figure 4(c) shows that AC005332.6, AC010894.1, AC068831.5, AL035446.1, AL513550.1, and HHLA3 were highly expressed in the high-risk OSCC group, while AC007114.1, HEIH, and LINC02541 were highly expressed in the low-risk OSCC group. These results suggested that this prognostic risk score model could accurately predict the prognostic risk outcomes of both groups of OSCC patients.

### 3.8. Validation of the Predictive Power of the Prognostic Risk Score Model
Forest maps and the ROC curve were generated to verify the predictive power of the prognostic risk score model. According to Figures 5(a) and 5(b), $P$ values of risk score were less than 0.05 and HR values were greater than 1 in both univariate and multivariate independent prognostic analyses, suggesting that risk score in the prognostic risk score model may be a reliable clinical independent prognostic factor. As shown in Figure 5(c), the risk score had the highest AUC value (0.931) compared to other clinical trait parameters. These results suggested that the prognostic risk score model has the ability to predict the prognosis of OSCC patients accurately and independently.

### 4. Discussion
Factors that influence the recurrence of OSCC have been extensively explored in recent years. Cai et al. [40] have
analyzed the patient clinicopathologic data, including tumor sites, clinical and pathologic stage, histological grade, invasion mode, and perineural invasion. They have concluded that tongue cancer and poor differentiation contributed to OSCC recurrence after surgery. Xia et al. [41] have reported that the recurrence rate was 44.9% in 118 patients with OSCC. Statistical analysis showed that comorbidities, degree of tumor differentiation, and tumor stage were important prognostic factors for recurrence. In this paper, 31 m7G-related mRNAs and 399 m7G-related lncRNAs were obtained through coexpression network analysis. Afterwards, we performed univariate Cox analysis on 16 m7G-related prognostic lncRNAs and optimized 9 m7G-related prognostic lncRNAs, and the prognostic risk score model of OSCC patients was evaluated and optimized through cross-validation. Further, through the coexpression analysis and risk assessment analysis of m7G-related prognostic mRNAs and lncRNAs, it was found that six m7G-related prognostic lncRNAs (AC005332.6, AC010894.1, AC068831.5, AL035446.1, AL513550.1, and HHLA3) were

Figure 3: The survival curve of high (red) and low (blue) expression groups of m7G-related prognostic lncRNAs. Abscissa: survival years of patients; ordinate: survival rate of patients.
high-risk lncRNAs. Three m7G-related prognostic lncRNAs (AC007114.1, HEIH, and LINC02541) were protective lncRNAs. Then, survival curves were drawn by comparing the survival differences between patients with high and low expression of each m7G-related prognostic lncRNA in the prognostic risk score model. Further, risk curves, scatter plots, and heat maps were drawn by comparing the survival differences between high-risk and low-risk OSCC patients in the prognostic model. Finally, forest maps and the ROC curve were generated to verify the predictive power of the prognostic risk score model.

So far, no study has reported the risk correlation between m7G-related lncRNAs and survival prognosis of OSCC based on bioinformatics analysis. However, in other areas of cancer, a few studies have found that m7G-modification is involved in gene regulation of tumor cell biology. Chen et al. [10] conducted tRNA modification and expression profile, mRNA translation profile, and rescue analysis in a conditional gene knockout mouse model and found that abnormal translation regulated by METTL1/WDR4-mediated tRNA m7G-modification drives the development and progression of squamous cell carcinoma of the head and neck. Xia et al. [41] verified the high expression of WD repeat Domain 4 (WDR4) in hepatocellular carcinoma (HCC) by cell culture and functional experiments and observed that upregulated WDR4 expression increased m7G-methylation level in HCC. And HCC cell proliferation was promoted by inducing G2/M cell cycle conversion and inhibiting apoptosis. Liu et al. [42] confirmed that methyltransferase-like 1 (METTL1) acts as a tumor suppressor in colon cancer by activating m7G-regulated let-7e miRNA/HMG2 axis through quantitative PCR, Western
**Figure 5: Continued.**
blot, CCK-8 assay, transwell assay, and dual-luciferase reporter gene system. To our knowledge, this study has manifested the risk correlation between N7-methylguanosine modification-related lncRNAs and survival prognosis of oral squamous cell carcinoma for the first time. Our data has identified m7G-related lncRNAs through coexpression analysis and the m7G-related prognostic lncRNAs by KM analysis and univariate Cox analysis methods. Then, a prognostic risk score model for OSCC were constructed and obtained the formula of the model. Next, coexpression network analysis, risk assessment, and survival analysis of m7G-related prognostic lncRNAs were carried out. In addition, we conducted a comprehensive risk analysis for OSCC patients with high- and low-risk groups and performed independent prognostic analyses and ROC curve analyses to verify the predictive performance of OSCC prognostic risk score model.

However, there are still some limitations in this study, such as the lack of further studies on the important functions and key pathways of different pathological subtypes of OSCC and m7G-related gene [43]. More experimental validation of tissue samples from patients is needed in the future to further validate our new findings.

**Data Availability**

The dataset used and/or analyzed during this study may be granted by contacting the corresponding author.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Yanglong Xu and Xue Zou contributed equally to this study.

**Acknowledgments**

The authors thank the TCGA database for providing the valuable gene expression matrix and clinical information of OSCC.

**Supplementary Materials**

Supplementary Materials. File m7G-lncRNAs_exp.xls shows the expression matrix of 399 m7G-related lncRNAs. Rows represent m7G-related lncRNA names, and columns represent samples. File co-exp_rel.xls shows the coexpression relationship of m7G-related lncRNAs and m7G-related mRNAs. The first column represents m7G-related mRNAs, the second column represents m7G-related lncRNAs, the third column represents coexpression correlation coefficients, and the fourth column represents the $P$ value of the correlation test. File risk.xls presents univariate Cox regression analysis for 16 significant m7G-related prognostic lncRNAs. The first column represents samples, the second column represents the survival time of patients, the third column represents the risk score, and the fourth column represents the hazard ratio.
column represents their survival status, and columns 4 to 19 represent m7G-related prognostic lncRNAs. File risk.xls presents the risk scores of nine m7G-related prognostic lncRNAs that constitute the prognostic model. The first column represents samples, the second column represents the survival time of patients, the third column represents their survival status, columns 4 to 12 represent m7G-related prognostic lncRNAs, and columns 13 and 14 represent the risk score and risk grouping for each patient. File coexp_network.xls shows the coexpression relationship between the m7G-related prognostic lncRNAs and mRNAs. The first column represents prognostic m7G-related mRNAs, the second column represents prognostic m7G-related lncRNAs, and the third column represents the correlation type. (Supplementary Materials)

References

[1] Q. Duan, M. Xu, M. Wu, X. Zhang, M. Gan, and H. Jiang, “Long noncoding RNA CDA1 promotes cell growth, migration, and invasion by targeting miR-143-3p in oral squamous cell carcinoma,” Cancer Medicine, vol. 9, no. 9, pp. 3115–3129, 2020.

[2] R. Siegel, K. Miller, H. Fuchs, and A. Jemal, “Cancer statistics, 2022,” CA: a Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, 2022.

[3] H. Suenaga, H. Hoang Tran, H. Liao et al., “Notch signaling induces EMT in OSCC cell lines in a hypoxic environment,” Oncology Letters, vol. 6, no. 5, pp. 1201–1206, 2013.

[4] J. Xiao, H. Lai, S. Wei, Z. Ye, F. Gong, and L. Chen, “IncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCRA4 and RhoA signaling pathway,” Cancer Medicine, vol. 8, no. 15, pp. 6768–6779, 2019.

[5] Q. Yang, J. Wang, P. Zhong et al., “The clinical prognostic value of IncRNA FAM83H-AS1 in cancer patients: a meta-analysis,” Cancer Cell International, vol. 20, no. 1, p. 72, 2020.

[6] S.‐Y. Zhang, S.-W. Zhang, T. Zhang, X.-N. Fan, and J. Meng, “Recent advances in functional annotation and prediction of the epitranscriptome,” Computational and Structural Biotechnology Journal, vol. 19, pp. 3015–3326, 2021.

[7] V. H. Cowling, “Regulation of mRNA cap methylation,” The Biochemical Journal, vol. 425, no. 2, pp. 295–302, 2009.

[8] X. Ying, B. Liu, Z. Yuan et al., “METTL1-m7G-EGFR/EFEMP1 axis promotes the bladder cancer development,” Clinical and Translational Medicine, vol. 11, no. 12, p. e675, 2021.

[9] O. Katsara and R. J. Schneider, “m’G RNA modification reveals new secrets in the translational regulation of cancer development,” Molecular Cell, vol. 81, no. 16, pp. 3243–3245, 2021.

[10] Z. Chen, W. Zhu, S. Zhu et al., “METTL1 promotes hepatocarcinogenesis via m7G RNA modification-dependent translation control,” Clinical and Translational Medicine, vol. 11, no. 12, p. e661, 2021.

[11] Z. Dai, H. Liu, J. Liao et al., “N7-methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression,” Molecular Cell, vol. 81, no. 16, pp. 3339–3355.e8, 2021.

[12] C. Ganini, I. Amelio, R. Bertolo et al., “Global mapping of cancers: The Cancer Genome Atlas and beyond,” Molecular Oncology, vol. 15, no. 11, pp. 2823–2840, 2021.

[13] J. Lee, “Exploring cancer genomic data from the cancer genome atlas project,” BMB Reports, vol. 49, no. 11, pp. 607–611, 2016.

[14] A. Liberzon, A. Subramanian, R. Pinchback, H.Thorvaldsdottir, P. Tamayo, and J. Mesirov, "Molecular Signatures Database (MSigDB)," Bioinformatics (Oxford, England), vol. 27, no. 12, pp. 1739-1740, 2011.

[15] M. Ritchie, B. Shipson, D. Wu et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, article e47, 2015.

[16] S. Qin, Y. Liao, Q. Du et al., “DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer,” Cancer Cell International, vol. 20, no. 1, p. 206, 2020.

[17] M. Wu, Y. Xia, Y. Wang et al., “Development and validation of an immune-related gene prognostic model for stomach adenocarcinoma,” Bioscience Reports, vol. 40, no. 10, 2020.

[18] Z. Hu, D. Yang, Y. Tang et al., “Five-long non-coding RNA risk score system for the effective prediction of gastric cancer patient survival,” Oncology Letters, vol. 17, no. 5, pp. 4474–4486, 2019.

[19] S. Li, L. Wang, Q. Zhao et al., “Genome-wide analysis of cell-free DNA methylation profiling for the early diagnosis of pancreatic cancer,” Frontiers in Genetics, vol. 11, p. 596078, 2020.

[20] Y. Zhang, X. Zhang, X. Lv et al., “Development and validation of a seven-gene signature for predicting the prognosis of lung adenocarcinoma,” BioMed Research International, vol. 2020, Article ID 1836542, 10 pages, 2020.

[21] R. Dobrin, J. Zhu, C. Molony et al., “Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease,” Genome Biology, vol. 10, no. 5, p. R55, 2009.

[22] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.

[23] B. P. Turnwald, J. P. Goyer, D. Z. Boles, A. Silder, S. L. Delp, and A. J. Crum, “Learning one’s genetic risk changes physiology independent of actual genetic risk,” Nature Human Behaviour, vol. 3, no. 1, pp. 48–56, 2019.

[24] K. Shameer, Y. Zhang, A. Prokop et al., “OSPred tool: a digital health aid for rapid predictive analysis of correlations between early end points and overall survival in non-small-cell lung cancer clinical trials,” JCO Clinical Cancer Informatics, vol. 6, no. 6, p. e2100173, 2022.
[28] S. Mangiola, M. Doyle, and A. Papenfuss, "Interfacing Seurat with the R Tidy Universe," Bioinformatics (Oxford, England), vol. 37, no. 22, pp. 4100–4107, 2021.

[29] G. Chen, G. Yang, J. Long et al., "Comprehensive analysis of autophagy-associated IncRNAs reveal potential prognostic prediction in pancreatic cancer," Frontiers in Oncology, vol. 11, p. 596573, 2021.

[30] B. George, S. Seals, and I. Aban, "Survival analysis and regression models," Journal of Nuclear Cardiology, vol. 21, no. 4, pp. 686–694, 2014.

[31] M. Wang, T. Xie, Y. Wu et al., "Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis," Oncology Letters, vol. 16, no. 4, pp. 4201–4210, 2018.

[32] G. D’Arrigo, D. Leonardis, S. Abd ElHafeez, M. Fusaro, G. Tripepi, and S. Roumeliotis, "Methods to analyse time-to-event data: the Kaplan-Meier survival curve," Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 2290120, 7 pages, 2021.

[33] P. Zhang, X. Tan, D. Zhang, Q. Gong, and X. Zhang, "Development and validation of a set of novel and robust 4-IncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis," PLoS One, vol. 16, no. 5, p. e0249951, 2021.

[34] R. Huang, J. Guo, P. Yan et al., "The construction of bone metastasis-specific prognostic model and co-expressed network of alternative splicing in breast cancer," Frontiers in Cell and Development Biology, vol. 8, p. 790, 2020.

[35] X. Qi, Z. Liu, Q. Zhang et al., "Systematic analysis of the function and prognostic value of RNA binding proteins in colon adenocarcinoma," Journal of Cancer, vol. 12, no. 9, pp. 2537–2549, 2021.

[36] Q. Zhang, G. Guan, P. Cheng, W. Cheng, L. Yang, and A. Wu, "Characterization of an endoplasmic reticulum stress-related signature to evaluate immune features and predict prognosis in glioma," Journal of Cellular and Molecular Medicine, vol. 25, no. 8, pp. 3870–3884, 2021.

[37] Y. Yue, K. Astvatsaturyan, X. Cui, X. Zhang, B. Fraass, and S. Bose, "Stratification of prognosis of triple-negative breast cancer patients using combinatorial biomarkers," PLoS One, vol. 11, no. 3, p. e0149661, 2016.

[38] K.-H. Pan, L. Jian, W.-J. Chen et al., "Diagnostic performance of contrast-enhanced ultrasound in renal cancer: a meta-analysis," Frontiers in Oncology, vol. 10, p. 586949, 2020.

[39] Y. Zheng, Y. Wen, H. Cao et al., "Global characterization of immune infiltration in clear cell renal cell carcinoma," Oncotargets and Therapy, vol. 14, pp. 2085–2100, 2021.

[40] S. Cai, X. Hu, R. Chen, and Y. Zhang, "Identification and validation of an immune-related eRNA prognostic signature for hepatocellular carcinoma," Frontiers in Genetics, vol. 12, p. 657051, 2021.

[41] P. Xia, H. Zhang, K. Xu et al., "MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma," Cell Death & Disease, vol. 12, no. 7, p. 691, 2021.